Your new experience awaits. Try the new design now and help us make it even better

STUDY PROTOCOL article

Front. Psychol.

Sec. Neuropsychology

Volume 16 - 2025 | doi: 10.3389/fpsyg.2025.1650861

Efficacy of hybrid remote neuropsychological rehabilitation on cognitive complaints in post-therapeutic lower-grade glioma: the FREEDOME randomized study protocol

Provisionally accepted
Estelle  GUERDOUXEstelle GUERDOUX1,2,3*Louise  CoutantLouise Coutant1,3Sophie  GourgouSophie Gourgou3,4Caroline  MolleviCaroline Mollevi5Marie-Sophie  DucMarie-Sophie Duc3,6Fanny  SalascFanny Salasc3,6Hugues  DuffauHugues Duffau3,7,8Amélie  DarlixAmélie Darlix3,7,9
  • 1Department of palliative and supportive Care, Institut du Cancer de Montpellier (ICM), Montpellier, France
  • 2Laboratory Epsylon, EA4556, Universite Paul-Valery Montpellier 3, Montpellier, France
  • 3Universite de Montpellier, Montpellier, France
  • 4Bioetrics Unit, Institut du Cancer de Montpellier (ICM), Montpellier, France
  • 5Institut Desbrest d'Epidemiologie et de Sante Publique, Montpellier, France
  • 6Department of Clinical Research and Innovation, Institut du Cancer de Montpellier (ICM), Montpellier, France
  • 7Department of Medical Oncology, Institut du Cancer de Montpellier (ICM), Montpellier, France
  • 8Department of Neurosurgery, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
  • 9Institut de Genomique Fonctionnelle, Montpellier, France

The final, formatted version of the article will be published soon.

Lower-grade gliomas (LrGGs) are rare tumors that mainly concern young adults, with an overall survival ranging from 5 to 20 years and without any curative treatment to date. LrGGs are frequently associated with psychological disorders and neurocognitive impairments, including memory and dysexecutive syndrome, that can negatively affect professional, familial and social functioning, ultimately reducing the patients' health-related quality of life (HRQoL). Maintaining an acceptable HRQoL is a key objective because survival outcomes tend to be better in patients with fewer psychopathological comorbidities and better HRQoL. Neuropsychological rehabilitation and cognitive behavioral therapy (CBT) have shown promising results in patients with neurological conditions, mental health disorders, and cancer. However, they are not routinely used in patients with LrGG, and onco-neuro-psychologists (i.e., neuro-psychologists trained in oncology) with expertise in neurocognition and CBT are lacking. The aim of this study protocol is to evaluate the efficacy of the remote FREEDOME program, which integrates CBT and a digital neurocognitive tool, in patients with LrGG who experience cognitive complaints post-therapeutic phase. This ongoing, prospective, open-label, multicenter, randomized trial (1:2) should include 187 patients with LrGG considered "stable" (12 months after surgery, 6 months after chemotherapy or radiotherapy) and who are not planned to receive any cancer treatment in the first 4 months after enrollment. The primary objective is to assess the FREEDOME program effects on perceived cognitive impairment at month 4 post-inclusion. Secondary objectives include patient adherence to the intervention, and effects on the subjective and objective neurocognitive functioning, HRQoL (including sleep, fatigue and return-to-work) and psychopathological symptoms over time. The study will also explore the intervention effects on the patient memory and irritability, as perceived by family caregivers. This study may represent an important step in the implementation of evidence-based neuropsychological interventions tailored to the specific needs of patients with LrGG.

Keywords: Lower-grade glioma, Neuropsychological rehabilitation and remediation, cognitive behavioral therapy, Cognitive complaints, Remote Telehealth, health-related quality of life, Emotional disorders

Received: 20 Jun 2025; Accepted: 01 Sep 2025.

Copyright: © 2025 GUERDOUX, Coutant, Gourgou, Mollevi, Duc, Salasc, Duffau and Darlix. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Estelle GUERDOUX, Department of palliative and supportive Care, Institut du Cancer de Montpellier (ICM), Montpellier, France

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.